American Heart Journal
Volume 157, Issue 1 , Pages 149-155 , January 2009

Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: A randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study)

  • Braim M. Rahel, MD, PhD

      Affiliations

    • Department of Interventional Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
    • ,
  • Gerrit J. Laarman, MD, PhD

      Affiliations

    • Department of Interventional Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
    • ,
  • Johannes C. Kelder, MD

      Affiliations

    • Department of Research and Statistics, St. Antonius Hospital Nieuwegein, The Netherlands
    • ,
  • Juriën M. ten Berg, MD, PhD

      Affiliations

    • Department of Interventional Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
    • ,
  • Maarten J. Suttorp, MD, PhD, FACC

      Affiliations

    • Department of Interventional Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
    • Corresponding Author InformationReprint requests: Maarten J. Suttorp, MD, PhD, FESC, FACC, Department of Interventional Cardiology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands.

Received 22 May 2008 ,Accepted 20 August 2008.

References 

  1. Morice MC, Serruys PW, Sousa JE, et al. for the RAVEL Study Group A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  3. Grube E, Silber S, Hauptman KE, et al. TAXUS I: six- and twelve-month results from a randomised, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38–42
  4. Schampaert E, Cohen EA, Schlüter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110–1115
  5. Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099
  6. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients. A Sirius substudy. Circulation. 2004;109:2273–2278
  7. Neumann FJ, Desmet W, Grube E, et al. Effectiveness and safety of sirolimus-eluting stents in the treatment after coronary stent placement. Circulation. 2005;111:2107–2111
  8. Carter A, Aggarwal A, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617–624
  9. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents. Five-year results of the RAVEL trial. J Am Coll Cardiol. 2007;50:1299–1304
  10. Weisz G, Leon MB, Holmes DR, et al. Two-year outcomes after sirolimus-eluting stent implantation. Results from the SIRIUS trial. J Am Coll Cardiol. 2006;47:1350–1355
  11. Rahel BM, Suttorp MJ, Laarman GJ, et al. Primary Stenting of Occluded Native Coronary Arteries: final results of the PRISON study. Am Heart J. 2004;147:e22
  12. Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II). A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006;114:921–928
  13. TIMI study group. The thrombolysis and myocardial infarction (TIMI) trial: phase I findings. N Engl J Med. 1988;318:265–270
  14. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–1029
  15. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351
  16. Sirnes PA, Myreng Y, Mølstad P, et al. Improvement in left ventricular ejection fraction and wall motion after successful recanalization of chronic coronary occlusions. Eur Heart J. 1998;19:273–281
  17. Rambaldi R, Hamburger JN, Geleijnse ML, et al. Early recovery of wall motion abnormalities after recanalization of chronic totally occluded coronary arteries: a dobutamine echocardiographic, prospective, single-center experience. Am Heart J. 1998;136:831–836
  18. Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol. 2001;38:409–414
  19. Feres F, Munoz J, Abizaid A, et al. Angiographic and intravascular ultrasound findings of the late catch-up phenomenon after intracoronary beta-radiation for the treatment of in-stent restenosis. J Invasive Cardiol. 2005;17:478
  20. Hong MK, Mintz GS, Lee CW, et al. Late intravascular ultrasound findings of patients treated with brachytherapy for diffuse in-stent restenosis. Catheter Cardiovasc Interv. 2004;63:208–214
  21. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45:947–953
  22. Schampaert E, Moses JW, Schofer J, et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol. 2006;98:36–41
  23. Virmani R, Farb A, Kolodgie FD. Histopathologic alterations after endovascular radiation and antiproliferative stents: similarities and differences. Herz. 2002;27:1–6
  24. Babinska A, Markell MS, Salifu MO, et al. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant. 1998;13:3153–3159
  25. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–1521
  26. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113:1108–1113
  27. Moreno R, Fernández C, Hernández R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954–959
  28. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937–948
  29. Sirnes PA, Golf S, Myreng Y, et al. Stenting in chronic coronary occlusion (SICCO): randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol. 1996;28:1444–1451
  30. Rubartelli P, Niccoli L, Verna E, et al. Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. J Am Coll Cardiol. 1998;32:90–96
  31. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202
  32. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stent. JAMA. 2007;297:1992–2000
  33. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001–2009
  34. Werner GS, Richartz BM, Gastmann O, et al. Immediate changes of collateral function after successful recanalization of chronic total coronary occlusions. Circulation. 2000;102:2959–2965
  35. Zimarino M, Ausiello A, Contegiacomo G, et al. Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. J Am Coll Cardiol. 2006;48:59–65
  36. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stent. N Engl J Med. 2007;356:989–997
  37. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998-1008.
  38. Kastrati A, Julinda M, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039
  39. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019

 The PRISON II trial is registered with clinicaltrials.gov number NCT 00258596.

PII: S0002-8703(08)00746-1

doi: 10.1016/j.ahj.2008.08.025

American Heart Journal
Volume 157, Issue 1 , Pages 149-155 , January 2009

Article Tools

* Image Usage & Resolution